Lineage Cell Therapeutics, Inc.
LCTX
$1.11
$0.032.78%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.08M | 14.78M | 14.56M | 10.82M | 10.91M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.08M | 14.78M | 14.56M | 10.82M | 10.91M |
| Cost of Revenue | 20.59M | 18.96M | 17.88M | 13.15M | 13.08M |
| Gross Profit | -5.78M | -2.46M | -3.32M | -2.33M | -2.17M |
| SG&A Expenses | 19.35M | 18.69M | 18.46M | 18.01M | 18.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.93M | 37.65M | 36.34M | 31.16M | 31.31M |
| Operating Income | -26.85M | -22.87M | -21.78M | -20.34M | -20.40M |
| Income Before Tax | -37.39M | -69.29M | -68.65M | -67.51M | -40.76M |
| Income Tax Expenses | -5.28M | -5.28M | -5.28M | -- | -- |
| Earnings from Continuing Operations | -32.11 | -64.01 | -63.37 | -67.51 | -40.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -155.00K | -193.00K | -166.00K | -148.00K | -152.00K |
| Net Income | -32.26M | -64.21M | -63.53M | -67.66M | -40.91M |
| EBIT | -26.85M | -22.87M | -21.78M | -20.34M | -20.40M |
| EBITDA | -26.11M | -22.14M | -21.08M | -19.68M | -19.77M |
| EPS Basic | -0.14 | -0.28 | -0.28 | -0.30 | -0.18 |
| Normalized Basic EPS | -0.10 | -0.15 | -0.15 | -0.14 | -0.07 |
| EPS Diluted | -0.19 | -0.29 | -0.28 | -0.30 | -0.18 |
| Normalized Diluted EPS | -0.10 | -0.15 | -0.15 | -0.14 | -0.07 |
| Average Basic Shares Outstanding | 960.55M | 939.41M | 920.43M | 923.46M | 883.44M |
| Average Diluted Shares Outstanding | 988.67M | 955.55M | 920.43M | 923.46M | 883.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |